- Home
- CCSI vs ATXS Comparison
CCSI vs ATXS Comparison
Compare CCSI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCSI
- ATXS
- Stock Information
- Founded
- CCSI 2021
- ATXS 2008
- Country
- CCSI United States
- ATXS United States
- Employees
- CCSI N/A
- ATXS N/A
- Industry
- CCSI Retail: Computer Software & Peripheral Equipment
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- CCSI Technology
- ATXS Health Care
- Exchange
- CCSI Nasdaq
- ATXS Nasdaq
- Market Cap
- CCSI 450.6M
- ATXS 401.2M
- IPO Year
- CCSI N/A
- ATXS 2015
- Fundamental
- Price
- CCSI $21.60
- ATXS $6.38
- Analyst Decision
- CCSI Hold
- ATXS Strong Buy
- Analyst Count
- CCSI 5
- ATXS 7
- Target Price
- CCSI $27.20
- ATXS $32.43
- AVG Volume (30 Days)
- CCSI 138.8K
- ATXS 351.5K
- Earning Date
- CCSI 08-07-2025
- ATXS 08-11-2025
- Dividend Yield
- CCSI N/A
- ATXS N/A
- EPS Growth
- CCSI N/A
- ATXS N/A
- EPS
- CCSI 4.32
- ATXS N/A
- Revenue
- CCSI $349,374,000.00
- ATXS N/A
- Revenue This Year
- CCSI $1.20
- ATXS N/A
- Revenue Next Year
- CCSI $0.56
- ATXS N/A
- P/E Ratio
- CCSI $4.91
- ATXS N/A
- Revenue Growth
- CCSI N/A
- ATXS N/A
- 52 Week Low
- CCSI $16.67
- ATXS $3.56
- 52 Week High
- CCSI $32.10
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- CCSI 48.83
- ATXS 71.44
- Support Level
- CCSI $23.44
- ATXS $5.60
- Resistance Level
- CCSI $24.36
- ATXS $6.89
- Average True Range (ATR)
- CCSI 0.67
- ATXS 0.35
- MACD
- CCSI -0.03
- ATXS 0.09
- Stochastic Oscillator
- CCSI 37.30
- ATXS 94.51
About CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.